Integra Lifesciences Holdings (IART) Long-Term Deferred Tax (2009 - 2026)

Integra Lifesciences Holdings has reported Long-Term Deferred Tax for 18 years, with the latest figure at $70.4 million in Q2 2026.

• Quarterly Long-Term Deferred Tax fell 31.57% year-over-year to $70.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $70.4 million (down 31.57% YoY) and the FY2025 annual result came in at $69.9 million, up 100.02% from the prior year.
• Long-Term Deferred Tax rose to $70.4 million in Q2 2026 per IART's latest filing, from $68.1 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $109.7 million in Q3 2025 and troughed at $34.2 million in Q1 2024.
• A 5-year average of $56.9 million and a median of $50.4 million in 2022 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax sank 43.61% in 2022, then surged 124.95% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $46.0 million in 2022, then rose by 0.19% to $46.1 million in 2023, then dropped by 24.21% to $34.9 million in 2024, then surged by 100.02% to $69.9 million in 2025, then climbed by 0.84% to $70.4 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $70.4 million, $68.1 million, and $69.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.